Comment les acteurs moléculaires de la pathologie Alzheimer permettent de comprendre la démence ? Quelles conséquences diagnostiques et thérapeutiques ?
Journal article published in 2010 by
Luc Buee 
,
David Blum,
Stéphanie Bombois,
Valérie Buée-Scherrer,
Marie-Laure Caillet-Boudin,
Morvane Colin,
Vincent Deramecourt,
Claire-Marie Dhaenens,
Marie-Christine Galas,
Malika Hamdane,
Sandrine Humez,
Claude-Alain Maurage,
Florence Pasquier,
Bernard Sablonnière,
Susanna Schraen-Maschke
and other authors.
,
David Blum,
Stéphanie Bombois,
Valérie Buée-Scherrer,
Marie-Laure Caillet-Boudin,
Morvane Colin,
Vincent Deramecourt,
Claire-Marie Dhaenens,
Marie-Christine Galas,
Malika Hamdane,
Sandrine Humez,
Claude-Alain Maurage,
Florence Pasquier,
Bernard Sablonnière,
Susanna Schraen-Maschke
and other authors.
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
Alzheimer's disease is a neurodegenerative disorder characterized by neuropathological lesions: amyloid deposits and neurofibrillary degeneration. However, the links between these two brain hallmarks are still poorly understood. Until now, mainly amyloid pathology has been targeted un many clinical trials without any success. Both new therapeutic strategies and diagnosis improvement are needed.